

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)



(10) International Publication Number
WO 2025/210571 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/IB2025/053550

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

04 April 2025 (04.04.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/575,596	05 April 2024 (05.04.2024)	US
63/644,237	08 May 2024 (08.05.2024)	US
63/648,384	16 May 2024 (16.05.2024)	US
63/752,269	31 January 2025 (31.01.2025)	US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **JIANG, Haiyi**; ASTRAZENECA PHARMACEUTICALS LP, One Medimmune Way, Gaithersburg, Maryland 20878 (US). **SHIRE, Norah**; ASTRAZENECA PHARMACEUTICALS LP, One Medimmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG CANCER WITH PD-L1 INHIBITORS

(57) Abstract: The disclosure relates to methods of treating limited stage small-cell lung cancer.

WO 2025/210571 A1